

Video Series MANAGEMENT OF mHSPC: CLINICAL CASE STUDIES



'Patients have the right to know that we can do better than ADT alone in the lethal form of prostate cancer, so why should patients receive novel hormonal therapy upfront?'

Prof. Saad, 2022

Dear {{accTitle}} {{accFname}} {{accLname}},

I hope you enjoyed the speaker presentations on the management of mHSPC and the evidence for early intensification of treatment. I thought you might also be interested in the expert case studies available below that discuss the optimisation of mHSPC treatment.

Click on each speaker image to watch their presentation.



Prof. Laura-Maria Krabbe
Urologist, Münster,
Germany



Prof. Fred Saad
Urologist, Montreal,
Canada



Dr Neal Shore
Urologist, Myrtle Beach
SC, US



Prof. Bertrand Tombal
Urologist, Brussels,
Belgium

SUMMARY: the benefits of early treatment intensification.

- ◆ Treatment with ADT + NHT consistently improves survival rates in patients with mHSPC compared with ADT monotherapy^{1-7,9-12}
- ◆ Compared with ADT monotherapy, adding an NHT does not negatively impact patient-reported HRQoL^{1,12-14}
- ◆ ADT + NHT is the SOC for patients with mHSPC, irrespective of disease volume and risk^{*15-18}

ADT, androgen deprivation therapy; HRQoL, health-related quality of life; mHSPC, metastatic hormone-sensitive prostate cancer; NHT, novel hormonal therapy; SOC, standard of care; US, United States.

This meeting is fully funded and supported by Astellas, including faculty honoraria and the production of materials.

I will be in contact soon to set up an appointment. Please let me know if you are interested in further educational resources, similar to this programme.

Warm regards,

{{userPhoto}}

{{userName}}
{{User.Title}}

Astellas Pharma Australia Pty Ltd

Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113

Mobile: {{User.MobilePhone}}

Email: {{userEmailAddress}}

References: 1. Armstrong A, et al. *J Clin Oncol* 2019;37:2974–2986. 2. Davis ID, et al. *N Engl J Med* 2019;381:121–131. 3. Fizazi K, et al. *N Engl J Med* 2017;377:352–360. 4. James ND, et al. *Lancet* 2016;387:1163–1177. 5. Fizazi K, et al. *Lancet* 2022;30:1695–1707. 6. Chi KN, et al. *J Clin Oncol* 2021;39:2294–2303. 7. Smith RM, et al. *J Clin Oncol* 2022;40:13. 8. Sweeney C, et al. *N Engl J Med* 2015;373:737–746. 9. Armstrong A, et al. *J Clin Oncol* 2022;40:115. 10. Davis ID, et al. Presented at the ASCO Annual Meeting, 3–7 June 2022, Chicago, IL, US. Abstract LBA5004. 11. Stockler MR, et al. *J Clin Oncol* 2022;40:837–846. 12. Chi KN, et al. *Lancet Oncol* 2018;19:194–206. 13. Agarwal N, et al. *J Clin Oncol* 2021;39:5068. 14. Stenzl A, et al. *Eur Urol* 2020;78:603–614. 15. Sweeney C, et al. Presented at APCCC, 28–30 April 2022, Lugano, Switzerland. 16. European Association of Urology. Prostate Cancer Guidelines. Available at: <https://uroweb.org/guidelines/prostate-cancer/publications-appendices>. Last accessed: June 2023. 17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Version 4. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Last accessed: June 2023. 18. Morgans AK and Beltran H. *J Clin Oncol* 2022;40:818–824.

This email contains information about Astellas' products, services or events. For more information on how we use and protect your information, please read our [Privacy Policy](#). You have received this email because you have previously given consent to receive information regarding Astellas' products, services or events. You can withdraw your consent by clicking [unsubscribe](#), or by emailing our privacy officer at privacyofficer-au@astellas.com.

© 2024 Astellas Pharma Australia Pty Ltd. All rights reserved. Astellas Pharma Australia Pty Ltd.
ABN 81 147 915 482. Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113.

Date of preparation: June 2024. MAT-AU-OPC-2024-00005